京新药业(002020) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥870,570,379.68, representing a 1.52% increase compared to the previous year[5] - Net profit attributable to shareholders was ¥137,264,079.65, a 2.43% increase from the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥128,283,249.09, showing a significant increase of 23.12% year-on-year[5] - The net cash flow from operating activities reached ¥169,274,493.96, marking a substantial increase of 112.99% compared to the same period last year[5] - Total operating revenue for the current period reached ¥870,570,379.68, an increase of 1.23% compared to ¥857,514,892.19 in the previous period[27] - Net profit for the current period was ¥137,868,319.80, representing a 3.03% increase from ¥133,724,238.90 in the previous period[30] - The company reported a total comprehensive income of ¥138,090,753.91 for the current period, compared to ¥133,866,768.02 in the previous period[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,573,665,520.18, a decrease of 0.67% from the end of the previous year[7] - Total current assets decreased to ¥3,144,265,135.57 from ¥3,292,888,604.35[21] - Total non-current assets increased to ¥3,429,400,384.61 from ¥3,324,808,506.47[21] - Total liabilities amounted to ¥1,661,055,359.69, an increase from ¥1,639,127,704.24 in the previous period[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 46,641[14] - The largest shareholder, Lü Gang, holds 19.75% of shares, totaling 178,796,755 shares[14] - The equity attributable to shareholders was ¥4,890,800,998.04, down 1.36% from the previous year[7] - Total equity attributable to shareholders of the parent company was ¥4,890,800,998.04, a slight decrease from ¥4,958,326,790.13 in the previous period[24] Cash Flow - The company's cash and cash equivalents amount to ¥1,655,392,033.88, an increase from ¥1,558,668,597.33[18] - The cash received from operating activities was $879,444,379.12, down from $970,225,907.96, showing a decline in operational cash generation[34] - The total cash outflow from operating activities was $710,169,885.16, compared to $890,749,958.52 in the previous period, indicating a reduction in cash outflows[34] - Cash inflow from financing activities totaled $950,000.00, a decrease from $24,117,182.36 in the previous period, indicating reduced financing activity[37] - The net cash flow from financing activities was $884,532.86, a significant improvement from -$179,637,569.17 in the previous period, suggesting better management of financing[37] Operational Efficiency - The company reported a decrease in basic and diluted earnings per share to ¥0.16, a decline of 5.88% compared to the previous year[5] - The weighted average return on equity was 2.85%, down 0.49 percentage points from the previous year[5] - Total operating costs decreased to ¥725,127,219.20, down 1.65% from ¥739,345,608.91 in the previous period[27] - Research and development expenses for the current period were ¥79,224,664.20, up from ¥78,428,836.82 in the previous period[27] Investment Performance - The company experienced a 69.19% decrease in trading financial assets, primarily due to a reduction in purchased financial products[9] - The company reported a 40.02% increase in construction in progress, attributed to the addition of new engineering projects[9] - Total cash inflow from investment activities was $458,586,902.49, down from $567,471,397.58, indicating a decrease in investment cash inflows[34] - The net cash flow from investment activities was -$177,508,796.25, compared to a positive $195,167,783.21 in the previous period, showing a negative shift in investment performance[34] - The cash received from investment income was $38,291,284.04, an increase from $17,471,397.58, reflecting improved investment returns[34]